Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations

Figures & data

Table 1 Examples of Clinical Trials of Tebentafusp

Study Protocol	Patient Selection	Line	Primary Endpoint	Phase	Number of Patients	Clinical Trial Indentifier
Tebentafusp	mCM	2	MTD	I	84	NCT01211262
Tebentafusp, Durvalumab and/or Tremelimumab	mCM	2	Phase 1b: safety, DLT; Phase 2: ORR	Ib/II	312	NCT02535078
Tebentafup vs investigator’s choice	mUM	1	OS	III	378	NCT03070392
Tebentafusp	MRD CM and UM		MR	II	850	NCT05315258

Abbreviations: mCM, metastatic or advanced cutaneous melanoma; mUM, metastatic or advanced uveal melanoma; MRD, molecular relapsed disease; MTD, maximum tolerated dose; DLT, dose-limiting toxicity; ORR, objective response rate; OS, overall survival; MR, Molecular response.

Figure 1 Schematic overview of mechanism of action of tebentafusp.

Table 2 HLA Allele Frequencies of Various Populations, Among All Individuals (Left) and Among HLA-A*02 Positive Individuals (Right)

	Allele Frequency in Population (Including All HLA-A Alleles)								Allele Frequency in Population Among Individuals Who Have HLA-A2
Allele	AFA	API	EURO	MENA	HIS	NAM	UNK	All	AFA	API	EURO	MENA	HIS	NAM	UNK
A*02:01	11.88%	6.51%	27.11%	17.35%	19.86%	19.44%	21.82%	24.06%	66.00%	34.25%	95.56%	78.92%	75.41%	72.85%	87.23%
A*02:11	0.07%	5.12%	0.01%	0.32%	0.37%	0.73%	0.16%	0.46%	0.40%	26.94%	0.05%	1.47%	1.40%	2.75%	0.63%
A*02:02	4.02%	0.02%	0.08%	0.54%	0.62%	1.02%	0.46%	0.24%	22.34%	0.13%	0.27%	2.48%	2.35%	3.83%	1.84%
A*02:06	0.13%	2.44%	0.19%	0.46%	3.39%	2.57%	0.69%	0.57%	0.71%	12.83%	0.68%	2.07%	12.87%	9.62%	2.76%
A*02:05	1.62%	0.54%	0.75%	2.54%	1.32%	1.38%	1.36%	0.88%	9.03%	2.83%	2.65%	11.55%	5.00%	5.15%	5.43%
A*02:03	0.02%	1.99%	0.00%	0.03%	0.01%	0.07%	0.11%	0.17%	0.11%	10.49%	0.01%	0.13%	0.04%	0.25%	0.46%
A*02:07	0.01%	1.85%	0.02%	0.12%	0.02%	0.01%	0.19%	0.18%	0.05%	9.75%	0.07%	0.55%	0.06%	0.05%	0.76%
A*02:17	0.04%	0.00%	0.10%	0.47%	0.22%	0.52%	0.08%	0.10%	0.21%	0.02%	0.34%	2.14%	0.82%	1.93%	0.33%
A*02:04	0.04%	0.00%	0.00%	0.00%	0.24%	0.55%	0.04%	0.02%	0.20%	0.00%	0.01%	0.01%	0.92%	2.07%	0.15%
A*02:16	0.00%	0.38%	0.00%	0.01%	0.00%	0.01%	0.01%	0.03%	0.02%	2.01%	0.00%	0.03%	0.00%	0.02%	0.02%

Note: Data from Sacco et al.²¹

Abbreviations: AFA, African/African American; API, Asian/Pacific Islands; EURO, European/European descent; MENA, Middle East/North Coast of Africa; HIS, South or Central America/Hispanic/Latino; NAM, Native American populations; UNK, unknown/not asked/multiple ancestries/other; all, total of all populations; AUC, area under the curve; LS, least squares; NE, not estimable.

Sacco J, Carvajal R, Butler M, et al. 64MO - a phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). Ann Oncol. 2020;31:S1441–S1451. doi:10.1016/j.annonc.2020.10.552

 Google Scholar